These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma. Lin C; Li J; Wu C; Bao J J Mol Model; 2021 Feb; 27(3):91. PubMed ID: 33616795 [TBL] [Abstract][Full Text] [Related]
66. Identification of novel liver X receptor activators by structure-based modeling. von Grafenstein S; Mihaly-Bison J; Wolber G; Bochkov VN; Liedl KR; Schuster D J Chem Inf Model; 2012 May; 52(5):1391-400. PubMed ID: 22489742 [TBL] [Abstract][Full Text] [Related]
67. Nuclear receptor engineering based on novel structure activity relationships revealed by farnesyl pyrophosphate. Goyanka R; Das S; Samuels HH; Cardozo T Protein Eng Des Sel; 2010 Nov; 23(11):809-15. PubMed ID: 20817759 [TBL] [Abstract][Full Text] [Related]
68. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P; Chandra V; Rastinejad F Annu Rev Physiol; 2010; 72():247-72. PubMed ID: 20148675 [TBL] [Abstract][Full Text] [Related]
75. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832 [TBL] [Abstract][Full Text] [Related]
76. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity. Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179 [TBL] [Abstract][Full Text] [Related]